SIGA Technologies (SIGA Technologies) FCF Margin % : 67.85% (As of Dec. 2023)

View and export this data going back to 1997. Start your Free Trial

What is SIGA Technologies FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. SIGA Technologies's Free Cash Flow for the three months ended in Dec. 2023 was $79.0 Mil. SIGA Technologies's Revenue for the three months ended in Dec. 2023 was $116.5 Mil. Therefore, SIGA Technologies's FCF Margin % for the quarter that ended in Dec. 2023 was 67.85%.

As of today, SIGA Technologies's current FCF Yield % is 15.17%.

The historical rank and industry rank for SIGA Technologies's FCF Margin % or its related term are showing as below:

SIGA' s FCF Margin % Range Over the Past 10 Years
Min: -779.54 Med: 25.99 Max: 450.61
Current: 67.75

During the past 13 years, the highest FCF Margin % of SIGA Technologies was 450.61%. The lowest was -779.54%. And the median was 25.99%.

SIGA's FCF Margin % is ranked better than
98.73% of 1026 companies
in the Drug Manufacturers industry
Industry Median: -0.68 vs SIGA: 67.75

SIGA Technologies FCF Margin % Historical Data

The historical data trend for SIGA Technologies's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SIGA Technologies FCF Margin % Chart

SIGA Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-68.18

57.22

8.56

37.56

67.74

SIGA Technologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-71.37	293.73	-60.91	-55.21	67.85

Competitive Comparison of SIGA Technologies's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, SIGA Technologies's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SIGA Technologies's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SIGA Technologies's FCF Margin % distribution charts can be found below:

* The bar in red indicates where SIGA Technologies's FCF Margin % falls into.

SIGA Technologies FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

SIGA Technologies's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	94.777	/	139.917
	=	67.74 %

SIGA Technologies's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	79.032	/	116.481
	=	67.85 %

SIGA Technologies FCF Margin % Related Terms

Thank you for viewing the detailed overview of SIGA Technologies's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

SIGA Technologies (SIGA Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SIGA Technologies Inc (NAS:SIGA) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

31 East 62nd Street, New York, NY, USA, 10065

Website

http://www.siga.com

SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus.

Executives

Evan A. Knisely	director	C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Jay Varma	director	C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Ford Harold Eugene Jr.	director	4921 WILLIAM ARNOLD ROAD, MEMPHIS TN 38117
James Antal	director	30952 STEEPLECHASE DRIVE, SAN JUAN CAPISTRANO CA 92675
Holly L. Phillips	director	C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Gary J. Nabel	director	C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Julian Nemirovsky	director	35 EAST 62ND STREET, NEW YORK NY 10065
Edward P. Taibi	director	35 EAST 62ND STREET, NEW YORK NY 10065
Jaymie A Durnan	director	C/O SIGA TECHNOLOGIES, INC.,, 31 EAST 62ND STREET, NEW YORK NY 10065
Gomez Phillip Louis Iii	officer: Chief Executive Officer	7220 VAN NESS COURT, MCLEAN VA 22101
Daniel J Luckshire	officer: Executive VP & CFO	C/O SIGA TECHNOLOGIES, INC., 35 EAST 62ND STREET, NEW YORK NY 10065
Paul G Savas	director	35 EAST 62ND STREET, NEW YORK NY 10021
Julie Kane	director	77 BEALE ST, P.O. BOX 770000, SAN FRANCISCO CA 94177
Dennis E Hruby	officer: Chief Scientific Officer	SIGA TECHNOLOGIES, INC., 420 LEXINGTON AVENUE, SUITE 601, NEW YORK NY 10170
Michael J Bayer	director	1100 N GLEBE ROAD, ARLINGTON VA 22201